GF-AMY 10mg

For research use only — not for human or veterinary use.

Analytical Verification (COA)

Each batch of GF-AMY supplied by Grail Formula undergoes independent third-party laboratory verification to confirm compound identity, assay content, purity and microbiological safety.

Analytical testing for this batch was performed by Liquilabs s.r.o. (Czechia) using validated chromatographic and spectrometric techniques.

Batch: GF112025071

Key analytical results include:

• Assay Content: 10.49 mg
• Identification – Retention Time: 0.998
• Identification – Spectrum: 997
• Purity: greater than 99.8 percent
• Bacterial Endotoxins: below 0.001 EU per mg
• Total Aerobic Microbial Count: not detected
• Total Yeast and Mold Count: not detected

Independent heavy metal screening confirmed no detectable levels of arsenic, cadmium, cobalt, lead, nickel, mercury or vanadium.

These analytical procedures ensure traceability, purity verification and laboratory-grade compound consistency.

Product Overview

GF-AMY is a synthetic peptide frequently studied in controlled laboratory environments investigating metabolic signalling pathways and regulatory hormone systems.

The compound belongs to a class of peptide analogues associated with amylin signalling research and metabolic regulatory pathways.

This preparation contains 10 mg of high purity lyophilized peptide supplied in a sealed research vial. The lyophilization process preserves peptide stability and allows researchers to reconstitute the compound for controlled in vitro experimentation.

Because of its well-defined peptide structure and stable analytical profile, GF-AMY has become a commonly referenced compound in experimental metabolic and peptide signalling research models.

Compound Overview

GF-AMY is a synthetic long-acting analogue of the hormone amylin, a peptide hormone naturally co-secreted with insulin by pancreatic beta cells.

Within biochemical research models, amylin-related signalling pathways are studied for their role in metabolic regulation, gastrointestinal signalling and energy balance.

Research involving GF-AMY often focuses on how amylin receptor systems interact with broader metabolic signalling networks.

These investigations allow scientists to explore peptide-mediated regulatory mechanisms involved in metabolic homeostasis and cellular signalling systems.

Historical Background and Scientific Context

Scientific interest in amylin and related peptide signalling pathways expanded significantly during the late twentieth century as researchers explored hormonal regulators involved in metabolism.

During the 1980s and 1990s amylin was identified as a peptide hormone secreted alongside insulin that participates in metabolic signalling pathways.

Subsequent research led to the development of synthetic analogues designed to investigate amylin receptor signalling and metabolic regulatory mechanisms.

GF-AMY emerged as one such analogue used in laboratory models exploring peptide hormone signalling and metabolic regulatory pathways.

Mechanistic Focus in Research

Within experimental laboratory environments, GF-AMY is often studied in relation to peptide hormone signalling and metabolic regulatory networks.

Research investigations commonly explore the compound in experimental models examining:

• Amylin receptor signalling pathways
• Metabolic regulatory signalling networks
• Peptide hormone interaction dynamics
• Intracellular metabolic signalling models
• Comparative peptide analogue research
• Energy regulation signalling pathways
• Hormone-mediated cellular regulatory processes

These experimental models allow scientists to investigate molecular signalling mechanisms involved in metabolic regulation and peptide-mediated cellular communication.

Research Applications

In controlled research environments, GF-AMY may be utilised in experimental models designed to explore peptide hormone signalling and metabolic regulatory systems.

Examples of research applications include:

• Metabolic signalling pathway research
• Peptide hormone receptor studies
• Cell signalling pathway analysis
• Molecular metabolic regulation studies
• Comparative peptide analogue evaluation
• Biochemical signalling network modelling
• Controlled in vitro metabolic research

Grail Formula Quality

Every Grail Formula research compound is produced under strict quality control procedures designed to support reliable laboratory experimentation.

Each batch undergoes independent analytical testing to verify:

• Compound identity
• Assay accuracy
• Purity confirmation
• Microbial safety
• Endotoxin levels
• Heavy metal screening
• Full batch traceability

All testing is performed by independent laboratories to ensure transparent verification and reproducible research material.

Research Use Limitation

• Used solely for in vitro experiments
• Not permitted for clinical trials involving humans
• Not permitted for human or veterinary administration
• Not permitted for investigational human use

Verified and analysed with Liquilabs s.r.o. (Czechia)
High-purity GF-AMY research peptide
Validated assay content 10.49 mg with purity greater than 99.8 percent
Retention time and spectral identification confirmed
Endotoxin levels below 0.001 EU per mg
No detectable microbial growth or heavy metals
EU shipments include bacteriostatic water
For research use only — not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.